Vedastotug clinical trials
Also written BAT6026.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses Vedastotug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BAT6026
- 3
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Vedastotug.
- Dec 2026Evaluate the Safety, Tolerability of BAT6026Phase 1/2 · Bio-Thera Solutions
Studies
Open first, then newest update. How each study uses Vedastotug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Evaluate the Safety, Tolerability of BAT6026Active, not recruitingPhase 1/2Bio-Thera SolutionsNCT06094179Written as Monoclonal antibody BAT6026
- Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in ChinaCompletedPhase 1Bio-Thera SolutionsNCT05105971Written as BAT6026
- Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour PatientsTerminatedPhase 1Bio-Thera SolutionsNCT05109650Written as BAT6026